The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies
BackgroundAltered gut microbiome (GM) composition has been established in Parkinson’s disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies.ObjectivesTo investigate the temporal stability of GM profiles from PD patients on standa...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.875261/full |
| _version_ | 1818204321636941824 |
|---|---|
| author | Michal Lubomski Michal Lubomski Michal Lubomski Xiangnan Xu Xiangnan Xu Andrew J. Holmes Andrew J. Holmes Samuel Muller Samuel Muller Jean Y. H. Yang Jean Y. H. Yang Ryan L. Davis Carolyn M. Sue Carolyn M. Sue |
| author_facet | Michal Lubomski Michal Lubomski Michal Lubomski Xiangnan Xu Xiangnan Xu Andrew J. Holmes Andrew J. Holmes Samuel Muller Samuel Muller Jean Y. H. Yang Jean Y. H. Yang Ryan L. Davis Carolyn M. Sue Carolyn M. Sue |
| author_sort | Michal Lubomski |
| collection | DOAJ |
| description | BackgroundAltered gut microbiome (GM) composition has been established in Parkinson’s disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies.ObjectivesTo investigate the temporal stability of GM profiles from PD patients on standard therapies and those initiating device-assisted therapies (DAT) and define multivariate models of disease and progression.MethodsWe evaluated validated clinical questionnaires and stool samples from 74 PD patients and 74 household controls (HCs) at 0, 6, and 12 months. Faster or slower disease progression was defined from levodopa equivalence dose and motor severity measures. 19 PD patients initiating Deep Brain Stimulation or Levodopa-Carbidopa Intestinal Gel were separately evaluated at 0, 6, and 12 months post-therapy initiation.ResultsPersistent underrepresentation of short-chain fatty-acid-producing bacteria, Butyricicoccus, Fusicatenibacter, Lachnospiraceae ND3007 group, and Erysipelotrichaceae UCG-003, were apparent in PD patients relative to controls. A sustained effect of DAT initiation on GM associations with PD was not observed. PD progression analysis indicated that the genus Barnesiella was underrepresented in faster progressing PD patients at t = 0 and t = 12 months. Two-stage predictive modeling, integrating microbiota abundances and nutritional profiles, improved predictive capacity (change in Area Under the Curve from 0.58 to 0.64) when assessed at Amplicon Sequence Variant taxonomic resolution.ConclusionWe present longitudinal GM studies in PD patients, showing persistently altered GM profiles suggestive of a reduced butyrogenic production potential. DATs exerted variable GM influences across the short and longer-term. We found that specific GM profiles combined with dietary factors improved prediction of disease progression in PD patients. |
| first_indexed | 2024-12-12T03:39:23Z |
| format | Article |
| id | doaj.art-8521f0bebdc34906889e196bcd64bc47 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-12-12T03:39:23Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-8521f0bebdc34906889e196bcd64bc472022-12-22T00:39:42ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-05-011410.3389/fnagi.2022.875261875261The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted TherapiesMichal Lubomski0Michal Lubomski1Michal Lubomski2Xiangnan Xu3Xiangnan Xu4Andrew J. Holmes5Andrew J. Holmes6Samuel Muller7Samuel Muller8Jean Y. H. Yang9Jean Y. H. Yang10Ryan L. Davis11Carolyn M. Sue12Carolyn M. Sue13Department of Neurology, Royal North Shore Hospital, St Leonards, NSW, AustraliaDepartment of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW, AustraliaSchool of Medicine, The University of Notre Dame Australia, Sydney, NSW, AustraliaSchool of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, NSW, AustraliaThe Charles Perkins Centre, University of Sydney, Camperdown, NSW, AustraliaThe Charles Perkins Centre, University of Sydney, Camperdown, NSW, AustraliaSchool of Life and Environmental Sciences, University of Sydney, Camperdown, NSW, AustraliaSchool of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, NSW, AustraliaDepartment of Mathematics and Statistics, Macquarie University, Sydney, NSW, AustraliaSchool of Mathematics and Statistics, Sydney Precision Bioinformatics, University of Sydney, Camperdown, NSW, AustraliaThe Charles Perkins Centre, University of Sydney, Camperdown, NSW, AustraliaDepartment of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW, AustraliaDepartment of Neurology, Royal North Shore Hospital, St Leonards, NSW, AustraliaDepartment of Neurogenetics, Kolling Institute, Faculty of Medicine and Health, University of Sydney, St Leonards, NSW, AustraliaBackgroundAltered gut microbiome (GM) composition has been established in Parkinson’s disease (PD). However, few studies have longitudinally investigated the GM in PD, or the impact of device-assisted therapies.ObjectivesTo investigate the temporal stability of GM profiles from PD patients on standard therapies and those initiating device-assisted therapies (DAT) and define multivariate models of disease and progression.MethodsWe evaluated validated clinical questionnaires and stool samples from 74 PD patients and 74 household controls (HCs) at 0, 6, and 12 months. Faster or slower disease progression was defined from levodopa equivalence dose and motor severity measures. 19 PD patients initiating Deep Brain Stimulation or Levodopa-Carbidopa Intestinal Gel were separately evaluated at 0, 6, and 12 months post-therapy initiation.ResultsPersistent underrepresentation of short-chain fatty-acid-producing bacteria, Butyricicoccus, Fusicatenibacter, Lachnospiraceae ND3007 group, and Erysipelotrichaceae UCG-003, were apparent in PD patients relative to controls. A sustained effect of DAT initiation on GM associations with PD was not observed. PD progression analysis indicated that the genus Barnesiella was underrepresented in faster progressing PD patients at t = 0 and t = 12 months. Two-stage predictive modeling, integrating microbiota abundances and nutritional profiles, improved predictive capacity (change in Area Under the Curve from 0.58 to 0.64) when assessed at Amplicon Sequence Variant taxonomic resolution.ConclusionWe present longitudinal GM studies in PD patients, showing persistently altered GM profiles suggestive of a reduced butyrogenic production potential. DATs exerted variable GM influences across the short and longer-term. We found that specific GM profiles combined with dietary factors improved prediction of disease progression in PD patients.https://www.frontiersin.org/articles/10.3389/fnagi.2022.875261/fullgut microbiotagastrointestinal microbiomelongitudinalprogressiondevice-assisted therapieslevodopa-carbidopa intestinal gel |
| spellingShingle | Michal Lubomski Michal Lubomski Michal Lubomski Xiangnan Xu Xiangnan Xu Andrew J. Holmes Andrew J. Holmes Samuel Muller Samuel Muller Jean Y. H. Yang Jean Y. H. Yang Ryan L. Davis Carolyn M. Sue Carolyn M. Sue The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies Frontiers in Aging Neuroscience gut microbiota gastrointestinal microbiome longitudinal progression device-assisted therapies levodopa-carbidopa intestinal gel |
| title | The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| title_full | The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| title_fullStr | The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| title_full_unstemmed | The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| title_short | The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies |
| title_sort | gut microbiome in parkinson s disease a longitudinal study of the impacts on disease progression and the use of device assisted therapies |
| topic | gut microbiota gastrointestinal microbiome longitudinal progression device-assisted therapies levodopa-carbidopa intestinal gel |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.875261/full |
| work_keys_str_mv | AT michallubomski thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT michallubomski thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT michallubomski thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT xiangnanxu thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT xiangnanxu thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT andrewjholmes thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT andrewjholmes thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT samuelmuller thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT samuelmuller thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT jeanyhyang thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT jeanyhyang thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT ryanldavis thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT carolynmsue thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT carolynmsue thegutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT michallubomski gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT michallubomski gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT michallubomski gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT xiangnanxu gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT xiangnanxu gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT andrewjholmes gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT andrewjholmes gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT samuelmuller gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT samuelmuller gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT jeanyhyang gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT jeanyhyang gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT ryanldavis gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT carolynmsue gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies AT carolynmsue gutmicrobiomeinparkinsonsdiseasealongitudinalstudyoftheimpactsondiseaseprogressionandtheuseofdeviceassistedtherapies |